Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) and ADMA Biologics (NASDAQ:ADMA – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Jasper Therapeutics and ADMA Biologics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jasper Therapeutics | N/A | N/A | -$64.46 million | ($5.63) | -4.08 |
| ADMA Biologics | $330.24 million | 13.13 | -$28.24 million | ($0.02) | -935.50 |
Risk and Volatility
Jasper Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Profitability
This table compares Jasper Therapeutics and ADMA Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jasper Therapeutics | N/A | -64.68% | -56.10% |
| ADMA Biologics | 10.53% | 38.79% | 17.35% |
Analyst Recommendations
This is a summary of current recommendations for Jasper Therapeutics and ADMA Biologics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jasper Therapeutics | 0 | 0 | 10 | 0 | 3.00 |
| ADMA Biologics | 0 | 0 | 3 | 1 | 3.25 |
Jasper Therapeutics currently has a consensus price target of $73.00, indicating a potential upside of 217.81%. ADMA Biologics has a consensus price target of $15.50, indicating a potential downside of 17.16%. Given Jasper Therapeutics’ higher possible upside, equities analysts plainly believe Jasper Therapeutics is more favorable than ADMA Biologics.
Summary
ADMA Biologics beats Jasper Therapeutics on 9 of the 14 factors compared between the two stocks.
About Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
